NDAORALTABLETPriority Review
Approved
Jun 2025
Lifecycle
Launch
Competitive Pressure
0/100
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
YEZTUGO (lenacapavir sodium) is an oral small-molecule antiviral approved by the FDA in June 2025. It represents a novel mechanism of action in viral therapeutics delivered as a tablet formulation. Specific indications and mechanism details are under clinical evaluation.
Launch12.3 years to LOE
Early-stage launch phase offers high visibility and team expansion opportunity within Gilead's commercial organization.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Gilead Sciences is hiring 2 roles related to this product
Worked on YEZTUGO at Gilead Sciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.